US Stock MarketDetailed Quotes

ATRA Atara Biotherapeutics

Watchlist
  • 7.020
  • -0.150-2.09%
Close Mar 18 16:00 ET
  • 7.020
  • 0.0000.00%
Post 20:01 ET
41.13MMarket Cap-0.62P/E (TTM)

About Atara Biotherapeutics Company

Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which engages in the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. It also delivers off-the-shelf treatments to patients with high unmet medical need. Its product pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in Thousand Oaks, CA.

Company Profile

SymbolATRA
Company NameAtara Biotherapeutics
Listing DateOct 16, 2014
Issue Price11.00
Founded2012
CEODr. AnhCo Nguyen, PhD
MarketNASDAQ
Employees153
Fiscal Year Ends12-31
Address1280 Rancho Conejo Boulevard
CityThousand Oaks
ProvinceCalifornia
CountryUnited States of America
Zip Code91320
Phone1-805-623-4211

Company Executives

  • Name
  • Position
  • Salary
  • Dr. AnhCo Nguyen, PhD
  • President, Chief Executive Officer and Director
  • 2.28M
  • Eric Hyllengren
  • Executive Vice President, Chief Financial Officer, Chief Operating Officer and Principal Accounting Officer
  • --
  • Jill Henrich
  • Executive Vice President, Global Head Regulatory Affairs and Quality
  • --
  • Dr. Pascal Touchon, D.V.M.
  • Chairman of the Board
  • 4.38M
  • Matthew K. Fust
  • Independent Director
  • 239.73K
  • William K. Heiden
  • Independent Director
  • 237.23K
  • Gregory A. Ciongoli
  • Independent Director
  • --
  • Ameet Mallik
  • Independent Director
  • 219.52K
  • Dr. Carol G. Gallagher,Pharm.D.
  • Lead Independent Director
  • 260.23K
  • Dr. Maria Grazia Roncarolo, M.D.
  • Independent Director
  • 229.73K
Trending Stocks
Best Growth Stocks Best Growth Stocks

Spot stocks with huge growth potential and solid financial standing. Spot stocks with huge growth potential and solid financial standing.